Women with PMOS, formerly known as PCOS (polycystic ovary syndrome), face significantly elevated risks for heart attack and stroke compared to women without the condition. Recent research underscores that this hormonal disorder carries serious cardiovascular consequences beyond its reproductive effects.
PMOS affects roughly 8 to 13 percent of women of reproductive age. The condition disrupts insulin regulation and testosterone production, creating metabolic imbalances that damage cardiovascular health. Women with PMOS develop insulin resistance at higher rates, and this metabolic dysfunction directly increases plaque buildup in arteries.
The cardiovascular dangers emerge through multiple pathways. Elevated androgen levels promote inflammation and blood vessel dysfunction. Insulin resistance accelerates atherosclerosis development. Many women with PMOS also struggle with high blood pressure, elevated cholesterol, and obesity, all of which independently raise heart disease risk.
Studies show women with PMOS experience heart attacks and strokes at younger ages than their peers without the condition. This earlier onset demands proactive screening and intervention, particularly for women in their 40s and 50s who may not yet consider themselves at high cardiovascular risk.
The name change from PCOS to PMOS reflects updated understanding of the condition's complexity. The new terminology emphasizes that the disorder involves broader metabolic dysfunction beyond ovarian cysts alone.
Screening becomes essential for women with PMOS. Blood pressure monitoring, lipid panels, and glucose testing help identify emerging risk factors. Lifestyle modifications including regular exercise, Mediterranean-style eating patterns, and weight management reduce cardiovascular stress. Some women benefit from medications like metformin to improve insulin sensitivity, while others require blood pressure or cholesterol management.
Women diagnosed with PMOS should discuss cardiovascular risk assessment with their healthcare providers. Early detection and aggressive management of metabolic factors prevent premature heart disease. This condition demands a comprehensive